Uveal melanoma (UM) is a highly metastatic cancer that, in contrast to cutaneous melanoma, is largely unresponsive to checkpoint immunotherapy. Despite a well characterized genomic landscape and prognostically distinct molecular subtypes, a complete understanding of UM progression, metastasis and therapeutic resistance remains elusive.
Join Dr. J. William Harbour, Professor and Associate Director for Basic Science at Sylvester Comprehensive Cancer Center of the University of Miami, for a webinar to learn more about his recently published research studying the evolution of UM tumors and their microenvironments. Using single-cell approaches from 10x Genomics for gene expression, genomic copy number variation (CNV), and T- and B-cell receptor typing, Dr. Harbour and team comprehensively characterized eight primary tumors and three metastatic tumors revealing new insights into UM biology and identifying a new putative checkpoint inhibitor target, LAG3.
During this webinar you will learn about how Dr. Harbour and team:
- Explored the tumor microenvironment by analyzing gene expression profiles from 59,915 single cells from eight primary and three metastatic tumors to identify key gene expression differences across the tumor classes
- Used transcriptional trajectory analysis to elucidate the transcriptional states of cells, confirming defined states for class 1 and 2 primary tumors and suggesting phenotypic plasticity within tumors
- Combined single-cell T-cell receptor typing and gene expression data to reveal clonally expanded exhausted T-cell populations and identify LAG3 as a putative checkpoint inhibitor target